{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:09:53Z","timestamp":1783955393594,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dalian Municipal Medical Science Research Program Project, 2022","award":["2212018"],"award-info":[{"award-number":["2212018"]}]},{"name":"the Science and Technology Program Project of Liaoning Province","award":["2025JH2\/101800154"],"award-info":[{"award-number":["2025JH2\/101800154"]}]},{"name":"\"1+X\" Program Clinical Research Peak Project, The Second Affiliated Hospital of Dalian Medical University, 2024","award":["LCGF2024001"],"award-info":[{"award-number":["LCGF2024001"]}]},{"name":"Scientific Research Public Welfare Project Fund for High-Quality Development of Public Hospitals, China Health Promotion Foundation","award":["No.HXLX20240028"],"award-info":[{"award-number":["No.HXLX20240028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02182-8","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:15:23Z","timestamp":1779254123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed\/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation"],"prefix":"10.1007","volume":"26","author":[{"given":"Ming","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10388","key":"2182_CR1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"issue":"15","key":"2182_CR2","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang ES, Goldberg AD, Tallman M, Walter RB, Karanes C, Sandhu K, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-Mutated AML. J Clin Oncol. 2024;42(15):1776\u201387.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2182_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"4","key":"2182_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3324\/haematol.2025.288553","volume":"111","author":"NJ Short","year":"2026","unstructured":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, et al. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica. 2026;111(4):1246\u201353.","journal-title":"Haematologica"},{"issue":"13","key":"2182_CR5","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia. Clin Cancer Res. 2022;28(13):2744\u201352.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2182_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/ajh.25943","volume":"95","author":"G Borthakur","year":"2020","unstructured":"Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, et al. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020;95(11):1296\u2013303.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"2182_CR7","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1182\/blood-2023-185488","volume":"142","author":"E Kugler","year":"2023","unstructured":"Kugler E, Cohen I, Ram R, Canaani J, Amitai I, Shargian L, et al. Gilteritinib and venetoclax for relapsed\/refractory FLT3-Mutated acute myeloid leukemia - a real-world multicenter retrospective study. Blood. 2023;142(Supplement 1):5911\u20135911.","journal-title":"Blood"},{"issue":"35","key":"2182_CR8","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-Mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40(35):4048\u201359.","journal-title":"J Clin Oncol"},{"key":"2182_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107564","volume":"145","author":"Q Fu","year":"2024","unstructured":"Fu Q, Wang Y, Liu H, Gao H, Sun W, Jiang Q, et al. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3(mut) acute myeloid leukemia. Leuk Res. 2024;145:107564.","journal-title":"Leuk Res"},{"issue":"1","key":"2182_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","volume":"21","author":"KX Li","year":"2022","unstructured":"Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, et al. A novel approach for relapsed\/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022;21(1):66.","journal-title":"Mol Cancer"},{"issue":"6","key":"2182_CR11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2182_CR12","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1182\/blood-2024-203359","volume":"144","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhang X, Hou J, Shen L, Li F, Kong F, et al. Azacitidine, Homoharringtonine and Cytarabine combined with granulocyte colony-stimulating factor as frontline treatment for older patients with acute myeloid leukemia: a prospective, multicenter, single-arm Phase III study in China. Blood. 2024;144(Supplement 1):4280\u20134280.","journal-title":"Blood"},{"key":"2182_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1756-8722-2-32","volume":"2","author":"J Wang","year":"2009","unstructured":"Wang J, L\u00fc S, Yang J, Song X, Chen L, Huang C, et al. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol. 2009;2:32.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2182_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00432-010-0947-z","volume":"137","author":"LF Gu","year":"2011","unstructured":"Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, et al. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2011;137(6):997\u20131003.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2182_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164238","volume":"11","author":"M Xie","year":"2016","unstructured":"Xie M, Jiang Q, Li L, Zhu J, Zhu L, Zhou D, et al. HAG (Homoharringtonine, Cytarabine, G-CSF) regimen for the treatment of acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis with 2,314 participants. PLoS ONE. 2016;11(10):e0164238.","journal-title":"PLoS ONE"},{"issue":"1","key":"2182_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-023-00816-8","volume":"13","author":"F Saj","year":"2023","unstructured":"Saj F, Nisha Y, Ganesan P, Kayal S, Kar R, Halanaik D, et al. Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II study. Blood Cancer J. 2023;13(1):45.","journal-title":"Blood Cancer J"},{"issue":"25","key":"2182_CR17","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","volume":"119","author":"W Blum","year":"2012","unstructured":"Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025\u201331.","journal-title":"Blood"},{"key":"2182_CR18","doi-asserted-by":"crossref","unstructured":"Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G et al: Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. Cancers (Basel) 2025;18(1).","DOI":"10.3390\/cancers18010045"},{"key":"2182_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107693","volume":"153","author":"BJ Aubrey","year":"2025","unstructured":"Aubrey BJ, Blonquist T, McMasters M, Hobbs G, McAfee S, Rosenblatt J, et al. A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. Leuk Res. 2025;153:107693.","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"2182_CR20","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1182\/blood-2021-147349","volume":"138","author":"LA Potter","year":"2021","unstructured":"Potter LA, Galkin M, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, et al. An open-label Phase II trial of the combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the treatment of patients with relapsed\/refractory acute myelogenous leukemia. Blood. 2021;138(Supplement 1):2352\u20132352.","journal-title":"Blood"},{"key":"2182_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1142449","volume":"13","author":"C Zhang","year":"2023","unstructured":"Zhang C, Gao D, Wang X, Sun X, Yan Y, Yang Y, et al. Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial. Front Oncol. 2023;13:1142449.","journal-title":"Front Oncol"},{"issue":"7","key":"2182_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/blood-2015-05-646497","volume":"127","author":"C Larrue","year":"2016","unstructured":"Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127(7):882\u201392.","journal-title":"Blood"},{"issue":"5","key":"2182_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/cac2.12139","volume":"41","author":"C Glorieux","year":"2021","unstructured":"Glorieux C, Cui L, Zeng P, Xia X, Huang P. Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy. Cancer Commun (Lond). 2021;41(5):432\u20135.","journal-title":"Cancer Commun (Lond)"},{"key":"2182_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031248","author":"R Kleszcz","year":"2022","unstructured":"Kleszcz R, Paluszczak J. The Wnt signaling pathway inhibitors improve the therapeutic activity of glycolysis modulators against tongue cancer cells. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031248.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2182_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"},{"issue":"7","key":"2182_CR26","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","volume":"6","author":"CC Smith","year":"2022","unstructured":"Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144\u201355.","journal-title":"Blood Adv"},{"issue":"12","key":"2182_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"12","key":"2182_CR28","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1158\/2159-8290.CD-23-0453","volume":"13","author":"P Bercier","year":"2023","unstructured":"Bercier P, Wang QQ, Zang N, Zhang J, Yang C, Maimaitiyiming Y, et al. Structural basis of PML-RARA oncoprotein targeting by Arsenic unravels a cysteine rheostat controlling PML body assembly and function. Cancer Discov. 2023;13(12):2548\u201365.","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"2182_CR29","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2021-147160","volume":"138","author":"DW Pierce","year":"2021","unstructured":"Pierce DW, Yao T-WS, Pace E, Wang H, Flandin-Blety P, Benitez A, et al. Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models. Blood. 2021;138(Supplement 1):3330\u20133330.","journal-title":"Blood"},{"issue":"5","key":"2182_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","volume":"137","author":"C Surka","year":"2021","unstructured":"Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, et al. CC-90009, a novel Cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021;137(5):661\u201377.","journal-title":"Blood"},{"issue":"3","key":"2182_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ajh.26447","volume":"97","author":"Y Numan","year":"2022","unstructured":"Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, et al. Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97(3):322\u20138.","journal-title":"Am J Hematol"},{"issue":"18","key":"2182_CR32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"2182_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2182_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41408-025-01353-2","volume":"15","author":"A Rajendra","year":"2025","unstructured":"Rajendra A, Smith E, Perusini MA, Tang K, Atenafu EG, Bankar A, et al. Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R\/R) AML: a Canadian single center analysis. Blood Cancer J. 2025;15(1):143.","journal-title":"Blood Cancer J"},{"issue":"13","key":"2182_CR35","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2182_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood-2012-02-407999","volume":"120","author":"J Fang","year":"2012","unstructured":"Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome\/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 2012;120(4):858\u201367.","journal-title":"Blood"},{"issue":"1","key":"2182_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, et al. Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol. 2023;16(1):42.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2182_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70089","volume":"4","author":"TT Liu","year":"2025","unstructured":"Liu TT, Chen LT, Pei XY, Hu SN, Zhuo FF, Chen ZK, et al. Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m(6)A-YTHDF2-dependent mechanism. Imeta. 2025;4(6):e70089.","journal-title":"Imeta"},{"key":"2182_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114538","volume":"188","author":"F Wang","year":"2021","unstructured":"Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, et al. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. Biochem Pharmacol. 2021;188:114538.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"2182_CR40","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/s41375-022-01678-y","volume":"36","author":"SE Koschade","year":"2022","unstructured":"Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th\u00f6lken M, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022;36(10):2396\u2013407.","journal-title":"Leukemia"},{"issue":"12","key":"2182_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood.2023023400","volume":"144","author":"S Suo","year":"2024","unstructured":"Suo S, Zhao D, Li F, Zhang Y, Rodriguez-Rodriguez S, Nguyen LXT, et al. Homoharringtonine inhibits the NOTCH\/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia. Blood. 2024;144(12):1343\u20137.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02182-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:01:41Z","timestamp":1783954901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02182-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involved retrospective analysis of human subjects with written informed consent obtained from all patients in accordance with institutional ethical standards and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participants have consented to the submission of the article to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"267"}}